Abstract: The present invention relates to a method for assaying antigen-specific T-cell responses through boosted flow cytometry and boosted ELISPOT technologies that are based on the use of specific combinations of monoclonal antibodies to stain simultaneously cytokines that in their combination identify specific T-cell polarization profiles. The method allows the identification of Tfc CD8+ T cell responses unrecognized so far.

Abstract: The present invention relates to novel immunogens based on overlapping peptides (OLPs) and peptides derived therefrom useful for the prevention and treatment of AIDS and its related opportunistic diseases. The invention also relates to isolated nucleic acids, vectors and host cells expressing these immunogens as well as vaccines including said immunogens.

Abstract: The present invention relates to immunogenic therapies for the treatment or prevention of a human immunodeficiency virus (HIV) infection or a disease associated with an HIV infection.

Abstract: The present invention relates to immunogenic therapies for the treatment or prevention of a human immunodeficiency virus (HIV) infection or a disease associated with an HIV infection.

Abstract: The present disclosure describes methods, compositions, and kits related to the combination of a TLR7 modulating compound and an HIV vaccine. The combination can be used in a method of treating or preventing an HIV infection in a human.

Abstract: The present invention relates to novel immunogens based on overlapping peptides (OLPs) and peptides derived therefrom useful for the prevention and treatment of AIDS and its related opportunistic diseases. The invention also relates to isolated nucleic acids, vectors and host cells expressing these immunogens as well as vaccines including said immunogens.

Abstract: The present invention relates to novel immunogens based on overlapping peptides (OLPs) and peptides derived therefrom useful for the prevention and treatment of AIDS and its related opportunistic diseases. The invention also relates to isolated nucleic acids, vectors and host cells expressing these immunogens as well as vaccines including said immunogens.

Abstract: The present invention relates to immunogenic therapies for the treatment or prevention of a human immunodeficiency virus (HIV) infection or a disease associated with an HIV infection.

Abstract: The present invention relates to novel immunogens based on overlapping peptides (OLPs) and peptides derived therefrom useful for the prevention and treatment of AIDS and its related opportunistic diseases. The invention also relates to isolated nucleic acids, vectors and host cells expressing these immunogens as well as vaccines including said immunogens.

Abstract: The present invention relates to novel immunogens based on overlapping peptides (OLPs) and peptides derived therefrom useful for the prevention and treatment of AIDS and its related opportunistic diseases. The invention also relates to isolated nucleic acids, vectors and host cells expressing these immunogens as well as vaccines including said immunogens.

Abstract: The present invention relates to novel immunogens based on overlapping peptides (OLPs) and peptides derived therefrom useful for the prevention and treatment of AIDS and its related opportunistic diseases. The invention also relates to isolated nucleic acids, vectors and host cells expressing these immunogens as well as vaccines including said immunogens.

Abstract: The present invention relates to novel immunogens based on overlapping peptides (OLPs) and peptides derived therefrom useful for the prevention and treatment of AIDS and its related opportunistic diseases. The invention also relates to isolated nucleic acids, vectors and host cells expressing these immunogens as well as vaccines including the immunogens.

Abstract: The invention relates to peptides comprising part or all of a conserved element within a Center-of-Tree (COT) sequence derived from a family of polypeptides encoded by naturally occurring variants of HIV. The invention also relates to immunogenic compositions and vaccines comprising said peptides. The invention also relates to methods for the identification of HIV controller patients based on the detection of the T cells of the patient to mount a cytotoxic T cell response against said peptides and to methods for the identification of immunogenic peptides within a family of variant polypeptides.

Abstract: The invention relates to a method and a diagnostic kit for monitoring HIV specific T cell responses and identifying subjects capable of controlling HIV progression or preventing HIV infection altogether. The method is based on the combined use of boosted flow cytometry and toggle peptides and can cover a large set of effector functions. The method is also suitable to detect T cell responses of any desirable cytokine or combination of cytokines to any pathogen.

Abstract: The invention relates to a method and a diagnostic kit for monitoring HIV specific T cell responses and identifying subjects capable of controlling HIV progression or preventing HIV infection altogether. The method is based on the combined use of boosted flow cytometry and toggle peptides and can cover a vastly larger set of effector functions than standard assays.

Abstract: The present invention relates to novel immunogens based on overlapping peptides (OLPs) and peptides derived therefrom useful for the prevention and treatment of AIDS and its related opportunistic diseases. The invention also relates to isolated nucleic acids, vectors and host cells expressing these immunogens as well as vaccines including the immunogens.

Abstract: The invention relates to peptides comprising part or all of a conserved element within a Center-of-Tree (COT) sequence derived from a family of polypeptides encoded by naturally occurring variants of HIV. The invention also relates to immunogenic compositions and vaccines comprising said peptides. The invention also relates to methods for the identification of HIV controller patients based on the detection of the T cells of the patient to mount a cytotoxic T cell response against said peptides and to methods for the identification of immunogenic peptides within a family of variant polypeptides.